Skip Navigation

Europace 2005 7(4):319-326; doi:10.1016/j.eupc.2005.02.117
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Senges-Becker, J. C.
Right arrow Articles by Schoels, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senges-Becker, J. C.
Right arrow Articles by Schoels, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

What is the "Optimal" follow-up schedule for ICD patients?

Julia C. Senges-Beckera, Martina Klostermanna, Ruediger Beckera,*, Alexander Bauera, Karl E. Sieglerb, Hugo A. Katusa and Wolfgang Schoelsa

aDepartment of Cardiology, University of Heidelberg Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; bAbteilung für Biometrie Herzzentrum Ludwigshafen, Germany

BACKGROUND: In the absence of comparative studies, recommended routine follow-up (FU) intervals for implantable cardioverter defibrillator (ICD) patients range from 1 to 6 months; most patients are followed at 3 month intervals.

METHODS: Six hundred and eighteen ICD patients were routinely seen 4 weeks after implant and then every 3 months. Unplanned visits (UPV) were either patient initiated or due to manufacturer recalls. FU visits included patient history/examination, ICD interrogation, pacing/sensing threshold and pacing/shock impedance. Chest X-rays were performed every 6 months. To validate FU interval recommendations, a comparative analysis on the detection of complications was performed, relying either on the information of every, or of every other FU visit, i.e., on 3 or 6 month intervals.

RESULTS: During 3.3 ± 2.8 years, 137 complications occurred in 110 patients (17%). However, identification of only 34% was dependent on the FU schedule, since the mode of detection was ICD interrogation in 38 and history/physical examination in nine patients. The remainder was diagnosed by UPV in 47, manufacturer recall in seven, accidental discovery during device replacement in two, and routine X-ray in 34 patients. Complication free survival at 2 years was 86.4% for patients implanted before 1999, and 89.2% thereafter (P = 0.003). Regarding 6 rather than 3 month FU intervals, a theoretical maximum delay of 3 months in the detection of potentially life-threatening complications would have occurred in 1.7% of all patients. For those implanted after 1999, this related to only 0.9%.

CONCLUSIONS: ICD-related complications detected during routine FU visits are relatively rare, particularly with newer generation ICD systems. Thus, 6 month FU intervals appear to be safe. With new developments such as patient alert features and telemedical data transmission, FU intervals in ICD clinics might even be further extended.

Key Words: implantable cardioverter defibrillator, routine follow-up, complications


*Corresponding author. Tel.: +49 6221 568855; fax: +49 6221 565514. E-mail address: ruediger_becker{at}med.uni-heidelberg.de (R. Becker).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62.
[Full Text] [PDF]


Home page
CirculationHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): e350 - e408.
[Full Text] [PDF]


Home page
JAMAHome page
P. J. Zimetbaum
A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator
JAMA, May 2, 2007; 297(17): 1909 - 1916.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. H. Schoenfeld
Contemporary Pacemaker and Defibrillator Device Therapy: Challenges Confronting the General Cardiologist
Circulation, February 6, 2007; 115(5): 638 - 653.
[Full Text] [PDF]


Home page
EuropaceHome page
A. Auricchio, M. Gropp, S. Ludgate, P. Vardas, J. Brugada, S. G. Priori, and Writing Committee for the European Heart Rhythm As
European Heart Rhythm Association Guidance Document on cardiac rhythm management product performance.
Europace, January 1, 2006; 8(5): 313 - 322.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.